Chemomab Therapeutics (NASDAQ:CMMB) Price Target Raised to $7.00

Chemomab Therapeutics (NASDAQ:CMMB) had its target price increased by equities research analysts at Maxim Group from $4.00 to $7.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price target would suggest a potential upside of 296.60% from the stock’s current price.

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $11.00 price objective (down from $13.00) on shares of Chemomab Therapeutics in a research note on Friday, November 15th.

Chemomab Therapeutics Stock Performance

Shares of NASDAQ:CMMB traded down $0.14 during trading on Thursday, reaching $1.77. The stock had a trading volume of 425,368 shares, compared to its average volume of 541,611. The firm’s fifty day moving average is $1.97 and its 200 day moving average is $1.70. Chemomab Therapeutics has a 52 week low of $0.58 and a 52 week high of $2.55. The stock has a market cap of $25.35 million, a price-to-earnings ratio of -1.75 and a beta of 0.66.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. XTX Topco Ltd increased its stake in shares of Chemomab Therapeutics by 63.8% in the fourth quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after buying an additional 9,706 shares during the period. Virtu Financial LLC purchased a new position in Chemomab Therapeutics during the 4th quarter valued at $26,000. Finally, Sphera Funds Management LTD. purchased a new position in Chemomab Therapeutics during the 3rd quarter valued at $1,907,000. 46.05% of the stock is owned by hedge funds and other institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).